DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
George Frey - 1 Dr Alexander Martin - 1 atezolizumab - 1 Marius Scholtz - 1 Genentech - 1 Roche - 1 Farouq Suleiman - 1 Sandra Maler - 1
Top related locs:
Genentech Salt Lake City , Utah U.S England West Suffolk
Top related orgs:
Huntsman Cancer Institute - 1 University of Utah - 1 REUTERS - 1 Medicines - 1 Healthcare - 1 Agency - 1 Foundation Trust - 1 Roche Products - 1

Search resuls for: "atezolizumab"


3 mentions found


☆ England to rollout world-first seven-minute cancer treatment jab
  + stars: | 2023-08-29 | by ( ) www.reuters.com   time to read: +2 min
Boxes of Tecentriq from Genentech are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S., July 22, 2022. REUTERS/George Frey/File Photo Acquire Licensing RightsAug 29 (Reuters) - Britain's state-run national health service will be the first in the world to offer an injection that treats cancer to hundreds of patients in England which could cut treatment times by up to three quarters. The treatment is currently offered by transfusion to NHS patients with a range of cancers, including lung, breast, liver and bladder. NHS England said it expected the majority of around 3,600 patients starting the treatment of atezolizumab every year in England to switch onto the time-saving injection. But added that patients receiving intravenous chemotherapy in combination with atezolizumab may remain on the transfusion.
Persons: George Frey, Dr Alexander Martin, atezolizumab, Marius Scholtz, Genentech, Roche, Farouq Suleiman, Sandra Maler Organizations: Huntsman Cancer Institute, University of Utah, REUTERS, Medicines, Healthcare, Agency, Foundation Trust, Roche Products, Thomson Locations: Genentech, Salt Lake City , Utah, U.S, England, West Suffolk
☆ This under-the-radar biotech stock can surge 40% on upcoming cancer treatment data, Wells Fargo says
  + stars: | 2023-03-09 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
It's time to buy Exelixis shares ahead of readouts on the biotech firm's cancer treatment, according to Wells Fargo. Analyst Derek Archila initiated coverage of Exelixis with an overweight rating, saying the biotech company's consistent revenue growth and upcoming clarity around the firm's cancer product called cabozantinib will drive upside. "We like cabo's near-term growth prospects and believe upcoming clarity on its [loss of exclusivity] will serve as a catalyst for shares. Exelixis shares are 2% higher this year, after falling 12% in 2022. EXEL 1D mountain Exelixis shares 1-day —CNBC's Michael Bloom contributed to this report.
☆ Brazilian soccer legend Pelé died of colon cancer. Here are the cutting-edge clinical trials trying to find new treatments for the disease.
  + stars: | 2022-12-30 | by ( Sarah Braner | ) www.businessinsider.com   time to read: +4 min
The Brazilian soccer legend Pelé died of colon cancer Thursday at 82. Colon cancer is the third most common cancer, affecting almost 2 million people each year. Colorectal cancer is the third most common cancer, according to the World Cancer Research Fund International. Pelé isn't the only celebrity to have died of colon cancer in recent years — the Black Panther star Chadwick Boseman died of the disease in 2020 at the age of 43. Here are the cutting-edge phase-three clinical trials for colon cancer, in order of how recently they began.
0 next >>
Total: 3